Research
Hormonal
Liraglutide treatment improved glycaemia as indicated by decreased C-peptide levels.
Liraglutide may help improve blood sugar levels in patients with type 2 diabetes.
StrongSupportsmedium confidence
In the liraglutide group, C-peptide decreased.
Why this rating
Based on the randomized, double-blind, placebo-controlled trial design.
Source
Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin–activin–follistatin– <scp>IGF</scp> ‐1 axis: Results from an exploratory, randomized, placebo‐controlled, crossover study
Valeria Gutierrez de Piñeres et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.70313
rct · n=20Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →